Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases

Medizin & Biologie

• Platelet-Rich Fibrin 100%
• Denosumab 93%
• Zoledronic Acid 86%
• Intercellular Signaling Peptides and Proteins 53%
• Neoplasm Metastasis 41%
• Bone and Bones 39%
• Epidermal Growth Factor 21%
• Wound Healing 19%
• Osteonecrosis 17%
• Acids 16%
• Jaw 15%
• Therapeutics 10%
• Healthy Volunteers 9%
• Becaplermin 9%
• Bone Remodeling 7%
• Vascular Endothelial Growth Factor A 6%
• Enzyme-Linked Immunosorbent Assay 5%
• In Vitro Techniques 3%